Credit Suisse Group upgraded shares of Humana (NYSE:HUM) from a neutral rating to an outperform rating in a research note issued to investors on Thursday, MarketBeat.com reports. The brokerage currently has $246.00 price target on the insurance provider’s stock, down from their prior price target of $264.90.

Several other research firms have also issued reports on HUM. Zacks Investment Research raised Humana from a hold rating to a buy rating and set a $297.00 price target on the stock in a research report on Monday, January 15th. ValuEngine lowered Humana from a buy rating to a hold rating in a research report on Tuesday, December 19th. BMO Capital Markets started coverage on Humana in a research report on Monday, October 16th. They set an outperform rating and a $300.00 price target on the stock. Cantor Fitzgerald reissued a hold rating and set a $250.00 price target on shares of Humana in a research report on Wednesday. Finally, Goldman Sachs Group started coverage on Humana in a research report on Wednesday, January 3rd. They set a buy rating and a $305.00 price target on the stock. Eight equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus target price of $269.68.

Shares of Humana (NYSE:HUM) traded down $0.57 on Thursday, hitting $261.80. The company’s stock had a trading volume of 784,809 shares, compared to its average volume of 1,191,541. Humana has a one year low of $203.36 and a one year high of $293.35. The firm has a market cap of $37,843.64, a price-to-earnings ratio of 15.73, a price-to-earnings-growth ratio of 1.54 and a beta of 0.93. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.61 and a current ratio of 1.85.

Humana (NYSE:HUM) last announced its earnings results on Wednesday, February 7th. The insurance provider reported $2.06 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.00 by $0.06. Humana had a return on equity of 16.13% and a net margin of 4.55%. The company had revenue of $13.19 billion for the quarter, compared to analyst estimates of $13.14 billion. During the same period in the prior year, the company posted $2.34 EPS. Humana’s quarterly revenue was up 2.4% on a year-over-year basis. analysts anticipate that Humana will post 13.75 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 27th. Investors of record on Friday, March 30th will be paid a dividend of $0.50 per share. This is an increase from Humana’s previous quarterly dividend of $0.40. This represents a $2.00 dividend on an annualized basis and a yield of 0.76%. The ex-dividend date is Wednesday, March 28th. Humana’s dividend payout ratio is presently 9.59%.

Humana declared that its Board of Directors has approved a share buyback program on Thursday, December 14th that authorizes the company to buyback $3.00 billion in shares. This buyback authorization authorizes the insurance provider to repurchase shares of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s board of directors believes its shares are undervalued.

In related news, SVP Jody L. Bilney sold 7,054 shares of the company’s stock in a transaction on Monday, December 18th. The stock was sold at an average price of $247.89, for a total transaction of $1,748,616.06. Following the completion of the transaction, the senior vice president now directly owns 11,704 shares in the company, valued at approximately $2,901,304.56. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, VP Timothy S. Huval sold 1,382 shares of the company’s stock in a transaction on Tuesday, December 19th. The stock was sold at an average price of $246.04, for a total value of $340,027.28. Following the transaction, the vice president now owns 11,557 shares of the company’s stock, valued at $2,843,484.28. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 10,115 shares of company stock valued at $2,501,627. 0.80% of the stock is owned by company insiders.

Several large investors have recently added to or reduced their stakes in HUM. WFG Advisors LP grew its stake in shares of Humana by 4.5% in the second quarter. WFG Advisors LP now owns 469 shares of the insurance provider’s stock worth $113,000 after purchasing an additional 20 shares in the last quarter. Fieldpoint Private Securities LLC bought a new position in shares of Humana in the third quarter worth $115,000. ClariVest Asset Management LLC bought a new position in shares of Humana in the third quarter worth $144,000. Daiwa SB Investments Ltd. grew its stake in shares of Humana by 44.9% in the fourth quarter. Daiwa SB Investments Ltd. now owns 710 shares of the insurance provider’s stock worth $176,000 after purchasing an additional 220 shares in the last quarter. Finally, Pettee Investors Inc. bought a new position in shares of Humana in the third quarter worth $207,000. 94.39% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This story was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this story on another publication, it was stolen and republished in violation of United States & international trademark & copyright laws. The correct version of this story can be accessed at https://www.watchlistnews.com/humana-hum-lifted-to-outperform-at-credit-suisse-group/1855337.html.

Humana Company Profile

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.